www.eurofins.com

EurofinsA global leader in bioanalytical testing in the food,

environment and pharmaceutical sectors

1

Corporate PresentationApril 2015

2

Disclaimer

The statements made during this presentation or as response to questions during the Question & Answers period that arenot historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on marketand competitive information available at a certain time. Forward looking statements and estimates represent the judgementof Eurofins Scientific’s management and involve risks and uncertainties including, but not limited to, risks associated with theinherent uncertainty of research, product/ service development and commercialisation, the impact of competitive productsand services, patents and other risk uncertainties, including those detailed from time to time in period reports, includingprospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities,that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligationor intention to release publicly any updates or revisions to any forward looking statement or estimate.

In addition, Eurofins provides in the Income Statement certain non-IFRS information (“Adjusted Results and SeparatelyDisclosed Items”) that excludes certain items because of their nature and the impact they have on the analysis of underlyingbusiness performance and trends. (Please refer to description of these terms in the Company’s Annual Report). Themanagement believes that providing this information enhances investors' understanding of the company’s core operatingresults and future prospects, consistent with how management measures and forecasts the company’s performance,especially when comparing such results to previous periods or objectives and to the performance of our competitors. Thisinformation should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS.

This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for orpurchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall formthe basis of, or be relied on in connection with, any offer or commitment whatsoever.

Analyst forecasts quoted are based on published analyst views. They are the responsibility of the investment banks whichpublish those forecasts and should not be interpreted as representing the views or expectations of Eurofins Scientific or theEurofins Scientific management. In particular, they do not constitute a profit forecast or estimate or trading statement byEurofins Scientific S.E. Similarly, objectives presented are only objectives and may not be achieved in reality, potentially by awide margin, due to a variety of factors.

3

� Introduction

� Market & Strategic Positioning

� Finance & Outlook

�Transaction Overview

� Summary

� Appendix

Contents

4

Eurofins’ Mission is to contribute to globalHealth, Safety & Environment with the best in bioan alysis

� Founded in 1987

� IPO in 1997 in Paris at EUR 1.83 per share

� Network of 200 laboratories in 36 countries

� Over 130,000 reliable analytical methods

� Over 17,000 employees

�Simplified shareholder structure: Martin Family 42% of share capital (59% of votingrights); Free float 58%

Key figures 2014 2009-2014 CAGRRevenues EUR 1,410m 17%Reported EBITDA EUR 230m 31%Op CashFlow EUR 212m 27%

*Adjusted – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”

Food

Environment Pharmaceuticals

Eurofins provides testing services in three main areas that have a strong impact on

human health:

“Recent trends in global food production, processing,distribution and preparation are creating an increasingdemand for food safety research in order to ensure asafer global food supply.” World Health Organisation

EUROFINS 2017: Mid Term ObjectivesEUR 2bn Revenues (12% CAGR from 2014)

>20% Adjusted EBITDA Margin

Market size estimate ~ EUR 4bn

*To the best of Eurofins’ knowledge, based on data available to the Group

~ EUR 2.0bn ~ EUR 5bn

N°1*worldwideStart 1987

N°1 to N°3* worldwide

Start 2000-2005

Testing forTesting forTesting forTesting forPharma/Pharma/Pharma/Pharma/BiotechBiotechBiotechBiotech

Environment Environment Environment Environment TestingTestingTestingTesting

Food & Food & Food & Food & Feed Feed Feed Feed

TestingTestingTestingTesting

N°1*worldwideStart 2000

Eurofins ranking

N° 1 in EuropeN° 1 in Germany N° 1 in France N° 1 in ScandinaviaN° 1 in BeneluxN° 1 in the UK**N° 1 in BrazilN° 2 in the USA**N° 1 in Agri Testing EU

N° 1 in Europe N° 1 in GermanyN° 1 in FranceN° 1 in ScandinaviaN° 1 in BeneluxN° 3 in USA

N° 1 Worldwide in Pharma Product TestingN° 1 Worldwide in Discovery Pharmacology ServicesAmong top 3 global providers of central laboratory, genomic and agrosciences servicesN° 1 or 2 in most segments/countries in Europe

** except routine Bacteriology - focus on high end a nalysis

New!

New!

5

New!

Leading global and local market positions

6

Demand for safe pharmaceuticals, quality food

and clean environment

Risks linked to global sourcing

and brand vulnerability

Consolidation of the fragmented laboratory

market and scale effects

Drivers for long-term market growth

Outsourcing of internal laboratories by industry

One-stop shopping (focus on few global testing suppliers)

Increasing wealth and quality of Life

Technological progress

Advancing globalisation

New analytical methods and lower

detection limits

Consumer expectations for

protection

Secular Underlying Fundamentals General Market Drivers Laboratory Market Drivers

7

Strong growth fueled by market growth, share gains and acquisitions

2006-2011 CAGR18%

-

200

400

600

800

1,000

1,200

1,400

1,600

1,800

2,000

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2017

2,000

RE

VE

NU

ES

EU

R m

CAGR5yrs 17%(2009-2014)

Objectives

CAGR10yrs 23%

(2004-2014)

2014-2017 CAGR12%

8

On track towards 2017 objectives

Eurofins 5 year Report Card: 2009-2014 CAGR

17.1%

20.6%

27.0%

Revenues Adjusted EBITDA Op CF

Achievements in 2014

� Ca. 6% organic growth versus 5% objective

� 19% increase in adjusted EBITDA to EUR 260m vs. EUR 250m objective

� 17 acquisitions with combinedrevenues in excess of €165m

� 25% increase in operating cash flows

2014: second year of our 5-year journey

� 15% revenue growth to EUR 1,410m (above EUR 1,400m objective)

� around 6% organic growth (around 7.5% excluding companies in significant restructuring)

� Sustained operating momentum in the group’s largest markets

� 17 acquisitions with total annualised revenues in excess of EUR 165m

� 19% increase in adjusted EBITDA; 60bp margin expansion

� 25% increase in Operating Cash Flow to EUR 212m

� 60,000m2 of world class lab surface added versus 40,000m 2 plan for 2014

� Entry into specialised, genomics-based diagnostic testing market via the acquisition of ViraCor-IBT and Boston Heart*

*Acquisition closed on 31 January, 2015

14.7%

12.6%

11.8%

0%

2%

4%

6%

8%

10%

12%

14%

16%

2012 2013 2014

Size of scope in restructuring is decreasing

Proportion of revenue contribution from start-ups &

businesses in significant restructuring

Separately Disclosed Items (SDI*) relative to EBITDA

of mature companies**

SDI include one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion,

start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative

goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects

Group adjusted

EBITDA margin

*

**The objective is for further significant reduction in 2015 onwards

9

Network Build-Out to Position for the Future

Lab surface

added m220,000 40,000 60,000

Faster site roll-out drives capex acceleration

2012 2013 2014

� 60,000m2 of modern lab surface delivered in 2014,

versus plan of 40,000m2

� 3 new sites; 6 major extension projects

� Strong progress in IT systems deployment

� eLIMS deployed in ca. 67% of Food and

Environment divisions

� OneIT almost fully deployed across Food and

Environment divisions

� Revised common Genomics and Agroscience IT

systems deployment on track for 2015

completion

� Eurofins On Line (EOL) almost fully deployed in

Food and Environment divisions

10

0%

5%

10%

15%

20%

€ m

€ 50m

€ 100m

€ 150m

€ 200m

2012 2013 2014To

tal A

nn

ual

ised

EB

ITA

S M

argi

n o

f Acq

uisi

tio

ns

Tota

l An

nu

alis

ed R

even

ues

of A

cqu

isit

ion

s

Network Build-Out to Position for the Future

2012-2014 Acquisitions

17 acquisitions completed in 2014

� Mostly high-growth and profitable

companies that provide Eurofins access to

new, promising growth markets

� Acquisitions were profitable and in many

cases above Group profitability level

� No restructuring required

0.8x 1.7x0.7x

Acquisition spend as a multiple of total revenues of acquisitions

11

12

Selective acquisitions to consolidate and secure leadership of our markets

Lancaster Laboratories (US, Europe, 2011)

IPL (France, 2011)

Nihon Kankyo (Japan, 2012)

Pan Labs (US, 2012), Cerep (France, 2013) and DDS Millipore (US, 2014)

NZ Labs (NZ, 2012) and mgt-Labmark (Australia, 2013)

Danone CLF (Germany, 2013)

Applus Agrofood Testing (Spain, 2014)

ViraCor IBT (USA, 2014)

Anatech (Brazil, 2014)

Boston Heart Diagnostics (USA, 2015)

� Global market leadership in pharma products testing

� Leading position in water testing in France

� Leading position in environment testing in Japan

� Create world leader in Discovery Pharmacology

� Strengthen Asia Pacific footprint

� Outsourcing for infant nutrition analysis, demonstrating Eurofins capabilities

� Leading position serving the Spanish food & retail industry

� Leveraging Eurofins’ genomics testing capabilities to expand into new market segment

� Reinforces Eurofins’ footprint in one of the world’s fastest-growing environmental testing markets

� Reinforces footprint in clinical diagnostics following acquisition of ViraCor IBT

Selected recent transactions Rationale/impact

13

An international network of world class, standardis ed laboratories is attractive for our customers

80% of the world’s population still has limited access to testing laboratories

N. America 25.3%

Germany 16.7%

France 16.1%

Others 14.7%

Nordic Region 11.4%

Benelux 10.2%

UK & Ireland 5.5%

2014 revenue split :

Entry into high-growth markets with start ups

& acquisitions

Geared towards strong economies and fast-growing markets

Geographical breakdown of Eurofins’ revenues in 2014

Germany

Austria

Switzerland

Benelux

Nordics

(Northern

Europe)

Germany

+

Northern

Europe

USA

+

APAC

& EM

Germany

Northern Europe

USA

APAC & EM

UK

&

Ireland

Total

Excluding

France &

Southern

Europe

France Italy Spain

Portugal

TOTAL

14

15

Eurofins’ strategy aims at building long lasting competitive advantages

� Extensive expertise in local regulations for all major markets, and one-stop contact for compliance in multiple countries

� Globally reliable standards of high quality and consistency

� International key accounts management

� Internet-based transactions and access to testing results

� Competence Centres & R&D activities

� Proprietary technologies for proof of origin, virus phenotyping & authenticity testing

� Continuous development/acquisition of advanced technologies

One stop shop

Leading technology

Pure-play laboratory operator

� International network with a presence in 36 countries

� Vast technological portfolio with more than 130,000 reliable methods

� Over 100 million assays performed per year

� But one contact person for each customer

� Industrialised processes

� Unrivalled expertise accessible to all customers

� Continually expanding geographical coverage

� Proven operating model that can be rolled-out in various/multiple markets

Quality of customer service

16

� Introduction

� Market & Strategic Positioning

� Finance & Outlook

�Transaction Overview

� Summary

� Appendix

Contents

17

Consumers’ increasing awareness and demand for safe and high quality food

The Food testing market has robust growth drivers

� Compels industry to strengthen its testing programs

� New products (GMOs, new packaging, etc.) create nee d for new tests

� Governments increase regulations on food control

� Brands have become more global and vulnerable to co ntaminations

� Transparency and traceability are becoming the prio rities

� Increasing pressure on producers and manufacturers to invest in testing

Food scares and crises, widely covered in the

media

Demand for a high quality, state-of-the-art, intern ational network of laboratories

Globalisation: Raw materials sourced

from countries with different QC

practices

Outsourcing of industry’s

internal or state-owned

laboratories

18

Retail & Distribution

Eurofins’ Food & Feed testing offering is the most comprehensive in the market

Agricultural production, product

development Production

Dioxins Veterinary drug residues

Organic residues POPs

Heavy metals Irradiation

Quality ControlVitamins

GMOLabelling

PurityNutritional

Microbiology Sensorial

Authenticity Pesticides

Mycotoxins Allergens

19

Year Brand/ Contamination Impact CostCountry

Salmonella in tomatoes and peppers

2008

E. Coli in cookie dough

70 people sick, 25 people hospitalized, job losses, withdrawal of 86 million "cookies-worth”, court proceedings initiated

50,000 infants ill, 6 deaths, global recall of dairy and related products, criminal charges in China

Melamine in dairy products

Sanlu/ Fronterra + global brands

~ USD 100-250m

Unquantified

2009

About 1,500 people sick throughout US & Canada – pulling of products from shops & restaurants

2008

Nestlé

North America/ Mexico

Dioxins Recall of Irish pork products, job losses, destruction of 100,000 pigs

2008

FreshPlaza

CNN Health

BBC News

Irish pork > EUR 300mIrish Exporters Association

Salmonella in peanut butter

2008 ~ USD 100m

Est. only for Kellogg’s

9 dead, 683 people sick, global recall of peanut butter and related products (1,600 types of products involved)

Kellogg’s, Unilever, General Mills

Bloomberg

High profile food scares have expensive consequence s for producers…

Dioxins in eggs, poultry and pork

About 3,000 tons of feed contaminated with oil inte nded for use in bio-fuels, 4700 farms closed, revenues l ost, tightening regulation

2011 Germany BBC news

Beef products contaminated with horse meat

Sales of frozen burgers plunged 43% and frozen ready meals fell 13% in the UK between 21 Jan –17 Feb, 2013, at the height of the scandal

2013 Europe The Guardian

~ EUR 360m

Market value lost for Tesco

20

Eurofins is meeting the demands of global players

� The largest global food & beverage producers and re tailers are clients of Eurofins

Food and Beverage Retailers2013 Sales in EUR billion

2013 Sales in EUR billion

Nestlé Switzerland 74.9Unilever UK /Netherlands 49.8PepsiCo USA 48.8Coca-Cola USA 34.4Mars* USA 25.0Danone France 21.3McDonalds USA 20.6Kraft Foods* USA 13.4Kelloggs USA 10.9Pernod Ricard France 8.6* estimates

Wal-Mart Stores USA 347.6Carrefour France 84.3CostCo USA 77.3Tesco UK 76.3Kroger USA 72.3Metro AG* Germany 65.4Aldi* Germany 57.0Lidl * Germany 56.7Casino Guichard France 48.6ITM Enterprises France 39.9

21

The Pharma testing market is both healthy and full of potential

� The increasing complexity of clinical trials leads to increasing amounts of diagnostic procedures performed per pate nt

� Regulatory bodies (e.g. FDA) are demanding more stu dy data to improve safety

� New wave of biologics require more testing

� Clinical trial processes are becoming increasingly rigorous to ensure drug efficacy

� The spend per drug trial is rapidly increasing

Need for big pharma companies to expand new drugs pipelines

Rapid technological change & increasing complexity in testing require ongoing investment in technology & expertise

Greater trial complexity & size will increase likeli hood of using CROs

22

Underlying trends are intact for continued growth

� Large pharmas need to refill their product pipeline as the ‘blockbusters’ start to come off patent

� Drug development expenditures have increased substantially in recent years

� Total R&D is over USD 120bn and is expected to further increase

� Sponsors outsource drug development to:- Reduce their fixed cost base- Access competencies that they do not have in-house- Access experience and regulatory expertise in new geographies

� Growth of biotechnology industry:- Limited physical infrastructure- Lack of internal expertise

Source: Citigroup Research 18 Feb, 2014

Source: Citigroup Research 18 Feb, 2014

Global Drug R&D Spending (US$ bn)

Total R&D Spend$ 140 bn

Portion that could beoutsourced

$ 80bn

Currently Outsourced

$34bn

Global % R&D Outsourced

23

Eurofins Pharma Services

Genomics DiscoveryPharmacology

Pre-clinical / Early

Development

Clinical (Central

Laboratory)

PharmaProducts Testing /

cGMP QC

Spanning the entire drug development cycle

SequencingOligonucleotides PharmacogenomicsTranscriptomicsGenotypingSNP-analysis

PharmacologyBioanalytical analysisTranslational medicinePhase I studies

BiomarkersBioanalysisImmunogenicityProteomicsMicrobiological and Anti-infective analysisBioavailabilityBioequivalence

Impurities AnalysisStability StudiesProcess developmentHygiene MonitoringPackaging analysis

Phases

I - IIIPhase IV,

Surveillance, Quality Control

Basic Research, Discovery,

Combinatorial,

Biological Product Libraries, etc

Pharmacology, Exploratory

Toxicology, PK, Metabolism,

etc

High-throughput-screeningMolecular-pharmacologycell-based assaysin vitro screeningin vitro profilingin vivo safetyin vivo efficacy

Specialty Clinical

Diagnostics

Cardiovascular Diseases

Immunodiagnostics

Infectious Diseases

Specific, fast-TAT testing for transplant patients

24

9 of the top 10 largest global pharmaceutical compa nies are clients of Eurofins

Top 10 pharma companies

PfizerSanofi AventisGlaxoSmithKline Novartis AstraZenecaMerck & CoJohnson & JohnsonRocheEli Lilly & Co Bristol-Myers Squibb

Global CRO Market

USA 60%

Europe 20%

Japan 8%

Rest of World 12%

Market

BreakdownCAGR*

12%

9%

18%

14%

Source: William Blair &Co.

* 2007 – 2012est.

Country

USAFranceUKSwitzerlandUKUSAUSASwitzerlandUSAUSA

Eurofins Pharma Locations

Clinical Diagnostics Services – a new source of grow th for Eurofins

• Enabling healthcare providers and patients to improve heart health and prevent disease with our integrated diagnostics, personalized reporting and lifestyle management solution

• Engaging reports and interactive tools and services helps improve health literacy and drive medication adherence, behavior change, and better outcomes

• Rapid growth in the last 5 years

• Accelerating medicine through innovative molecular and immunodiagnostics

• Providing clinical diagnostic solutions in infectious disease, allergy, hypersensitivity and immune disorders

• Working with vaccine, pharmaceutical, biotech and medical device developers

• Rapid TAT to hospital clients

Viracor IBT Boston Heart

• An exciting source of growth potential for Eurofins

• Focused on advanced innovative clinical diagnostics services

• Platform companies with seasoned leadership

• New line of business allowing entering into a new s trategic avenue

25

26

� Increasing demand by citizens for a clean environmen t

� EU expanding regulation (e.g. REACH)

� Increasingly long list of products identified as to xic

� Requirement for more sophisticated analyses and mor e expensive equipment

The Environmental testing market continues to grow

Rise in contamination & pollution issues

Progress in epidemiology & medicine has identified more compounds as toxic

Compels industry to increase testing and outsource internal labs

27

� Outdoor pollutants� Indoor and ambient

pollutants

Eurofins serves all the main environmental testing markets

SOILAIRWATER

Eurofins is the No.1 environmental testing service provider in the world*

� Drinking water and groundwater analysis

� Full range of contaminants

� Analysis of soil for full range of contaminants

Consulting and sampling companies are natural partners

Lancaster Environmental Testing is the laboratory of choice for Fortune 500

companies in the USA

* Management estimate based on available informatio n

28

Global trends in regulation support the business

� Strong regulated markets (EU, USA) are still amending and adding regulations

� Eastern European rules catching up with EU

� Fast development of regulation in Asia

� Regulation used for support of trading blocks (e.g. EU, NAFTA, ASEAN)

� European Food Regulation (EC)178/2002

Recently passed

� European REACH directive� US Country of Origin Labelling (COOL) law� PRC Food Safety Law in China� Food Safety Modernization Act (FSMA) in

USA

In the pipeline

� Comprehensive Review of Food Labelling Law and Policy in Australia & New Zealand

� Food imports

� Labelling (e.g. allergen, origin label, reference intakes)

� Foodstuffs (marketing standards for beverages, meat, fish, dairy products)

� Pesticides

� GMO & GM products

� Additives (vitamin & mineral fortification, flavourings, sweeteners, enzymes)

Key areas of food regulationMajor pieces of legislation

29

*Registration Evaluation and Authorisation of Chemicals(1): Regulation (EC) N° 1907/2006 and Directive 2006/121/EC of the European Parliament and of the Council

Metals, resins, acids, solvents, oils, fibres in textile, car

components, toys, cosmetics, plastics, rubber,

microchip, etc.

Food and drug ingredients are excluded

EU regulations a key driver for the testing industr y – e.g. REACH directive

� Listing and assessing the safety of 30,000chemical substances used by industries in Europe over 11 years

� Replacing the most dangerous ones - no chemical safety studies were conducted before 1981; only 3700 new chemicals analysed up to 2008 out of 100,000 used currently in EU

Time line

Physico-chemical properties: density, viscosity, etc.

Toxicity: skin, eye, mutagenicity, inhalation, oral,

reproductive

Ecotoxicity: invertebrates, plants, fish, birds, soil,

water, degradation

Increasing testing requirements from 2010

Objectives Examples of affected products or industries

Type of testing

Estimated cost

EUR 10bn according to the EU including EUR 1.5bn for testing over 11 years

> 1 t/ p.a.

production

> 100 t/ p.a.

production> 1,000 t/ p.a. production +

substances of very high concern

Nov 2010 May 2013 May 2018Deadlines for

registration

30

Outsourcing adds to market growth Examples of laboratories outsourced to Eurofins

Danish Hydrology Inst. Official water reference lab S candinavia

Suez/Sita Envirolab The Netherlands

Danish farmers association Steins’ water/environment laboratory Denmark

Southern Water Water testing laboratory UK

Lyon University Hospital Phase I Activity France

Austrian Research Institute Food testing Austria

Clermont University Mineral water analysis France

Raisio Group Food product testing Finland

Mondi Environmental, paper/pulp testing Slovakia

DLG Group Food and feed producer Denmark

Miljølaboratoriet Environmental testing network Denma rk

BASF/QTA Environmental, chemicals USA

MWH Global Environmental, water-testing USA

TÜV SÜD Dioxin Analysis Germany

Cranswick plc Food testing UK

Danone Infant and clinical nutrition analysis Germany

Company Outsourced Activity Country

31

Eurofins’ strategy builds high Barriers to Entry

� GLP� GMP� GCP

ISO 9001ISO 17025

FDA Approved

Offering a premium quality service … ... and leveraging internal efficiencies

� Portfolio : over 130,000 reliable methods –unique in the world and ahead of competition

� Global laboratory network : fully set up for cross-selling worldwide to customers

� Accreditations : multiple international accreditations

� One-stop shop : single point of contact for compliance to regulations of many countries

� Standardised testing in 36 countries

� Sales and marketing : international teams plus dedicated key account management

� Reputation : high standards of quality and consistency - the Eurofins brand

� Internet : web-based transactions and online access to testing results increase switching costs

� Industrialising the laboratory process: rationalisation of sites and personnel

� Competence Centres : high volume laboratories providing highest levels of expertise and service

� Technology : the latest available in the market providing the most accurate results

� Economies of scale in Group purchasing and sales functions

� IT systems : cross-Group information tools and standardised production systems

32

� Introduction

� Market & Strategic Positioning

� Finance & Outlook

�Transaction Overview

� Summary

� Appendix

Contents

� 100 new/expanded modern state-of-the-art sites to e nable consolidation / closure of smaller or old sites

� Total of ca. 300,000 m 2 added or brought to most modern standards between 2005 – 2014 (60,000 m 2 in 2014 alone)

� 100,000 m2 of additional modern laboratory surface planned for 2015-2016, of which over 40,000m 2 planned to come on stream in 2015 alone

Kalamazoo

Vallensbaek

Hamburg

Les Ulis

Saverne

Acton

Singapore

Ebersberg

2006 - 2009

Holsterbro

Lidköping

Rotterdam

Cuneo

Washington

Huntsville

Suzhou

Nantes

Denver

Princeton

Vejen

Malbork

Niefern

Sao Paolo

Major facilities : new or recently upgraded and pla nned for 2015-2016

2010 / 11

Cologne

Barneveld

Des Moines

Shanghai

Shenzhen

Tokyo

Nantes (Micro)

Ebersberg ext.

Wolverhampton

Saverne, FR ext.

Glostrup, DK

Melbourne, AU

Monrovia, CA

Garibaldi, BR

Mikkeli, FI

2012 2015 / 2016

Freiberg, DE

Ebersberg, DE ext.

Niefern, DE ext.

Reichenwalde,DE ext.

Douai, FR ext.

Saverne, FR ext.

Les Ulis, FR ext.

Moss, NO ext.

Uppsala, SE ext.

Boston, MA ext.

Louisville, KY

Hamburg, DE ext.

Nantes, FR ext

Aix-en-Provence, FR

Amsterdam, NL

Dungarvan, IE ext.

Lancaster, PA ext.

St. Charles, MO ext.

Des Moines, IA ext.

Auckland, NZ ext

Yokohama; JP ext

Hamburg, DE ext.

Seattle, WA

Vergeze, FR ext.

Graauw, NL

Wageningen, NL

2013

33

2014

Hamburg, DE ext.

Vejen, DK ext

Bangalore, IN

New Orleans, LA

Lancaster, PA ext.

Auckland, NZ

Sidney, AU

Bordeaux, FR

Mouds View, MN

Laboratory Network Investments:Expansion / Modernization of Laboratory Sites

Market Share: Eurofins is the leader in its industr y –and we continue to reach new market leadership posi tions

New Markets

= Market Entry

Denmark: Food and Env.

Brazil: Food Testing

France Environment Testing

USA: Pharma Products Testing

Sweden, Norway: Food and Env. Testing

Europe: Agroscience, Genomics

Japan: Genomics

Italy, Poland, Austria, Slovakia

Agri Testing Europe

Hungary, Finland

China, India, Singapore, Japan Environment

Australia, New Zealand

Global: Discovery Pharmacology

X No 1

2001 2002 2003 2004 2005 2006 2007 2008

Eurofins already has long-standing no.1 or no.2 posit ions in its main markets: e.g. Germany (Food + Env.), France (Food), Benelux (Food + Env.)

2009 2010 2011 2012

No 1

X No 1

X No 1

X No 1

X No 1

X No 1

X No 1/3

X

X

X

2013

X

X No 1

X

X

No 1

2014

34

35

� Start-ups: 17 start ups between 2006 and 2010

� Typically losses in years 1 and 2 of about EUR 1-2m p.a. per start-up

� Initial Capex EUR 1- 3m per lab (e.g. premises, equipment)

� Upgrade existing laboratories: ca. EUR 575m invested in additional capital in 2006-2014

Heavy investment in new markets and resources for future profits

� Deploy IT systems eLIMS, eCommerce (EOL)

� Best practice lab organisation & processes

� Consolidation into large, world-class sites

� Standardised testing procedures

� Invest in state-of-the-art technology

Under development perimeter Bringing recently acquired labs to group standards

Building corporate resource for future size and growth

� Recruitment of top leadership

� Additional layer of management to lead global business lines

� Central IT systems and processes

(e.g. ERP, CRM)

� Additional central cost+EUR 10m 2010 vs 2005+EUR 27m 2014 vs 2010

36

Positive trends drive solid operating results

Adjusted – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”.Separately disclosed items - includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects.

2014 2013+/- %

Adjusted

ResultsEURm

Adjusted

Results

Separately

disclosed

items

Statutory

Results

Adjusted

Results

Separately

disclosed

items

Statutory

Results

Revenues 1,410.2 1,410.2 1,225.6 1,225.6 15.1%

EBITDA 260.4 -30.4 230.0 219.3 -30.2 189.1 18.8%

EBITDA Margin (%) 18.5% 17.9% 60 bp

EBITAS 189.9 -41.2 148.7 161.9 -39.7 122.2 17.3%

Net Profit 128.2 -49.1 79.1 116.8 -44.6 72.2 9.8%

Basic EPS (€) 8.47 -3.25 5.23 7.79 -2.97 4.81 8.8%

Op. Cash Flow 212.2 169.3 25.3%

Capex 131.2 98.7

Net Debt 493.6 386.8

Net debt/adjusted

EBITDA

1.90x 1.76x

37

Strong underlying profitability enables investments

2014 EBITDA Composition EURm

Growth and Profitability are critical objectives

� 3-tiered margin support towards mid-term profitability objective

1. Start of profit contribution from start-ups

2. Proportion of companies in restructuring becoming smaller compared to the size of the Group (11.8% of total Group revenues in 2014 versus 12.6% in 2013 and 14.7% in 2012).

3. Investments in large industrialized laboratories unlock operational leverage

� A target “cruising altitude” of >20% adjusted EBITDA margin, in addition to top line growth should ensure continued earnings and cash flow growth

38

Group Profitability Objectives ++

*E – company objectives ++ Based on stated company objectives and assumes linear acquisitions until 2017

10%

12%

14%

16%

18%

20%

22%

0

500

1,000

1,500

2,000

2,500

2011 2012 2013 2014 2017E*

Gro

up

Ad

juste

d E

BIT

DA

ma

rg

in %

Gro

up

Re

ve

nu

es

Revenues from mature businesses Revenues from start-ups and companies in significant restructuring

Tangible Commitment from Internal Stakeholders

� In July 2014, Eurofins issued 117,820 warrants exclusively to its leaders

� Exercise Price €281.58

� Purchase Price €18.15

� Break-even Price €299.73

(in the money starting at €300)

� The warrants are not listed but giveaccess to new shares in Eurofins Scientific. The warrants are exercisable starting 01 July 2018, and are valid for 8 years as from July 2014.

� Eurofins will have the right to accelerate the exercise of the warrants from July 2018 onwards if the shareprice is above €506.84 (i.e. 180% of exercise price)

Upside/Downside for warrant holders

capital gain could becapped if exerciseacceleration is triggered by the company

39

� EUR 150m hybrid bond tap in July 2014 at 5% yield to call date (YTC) brings total hybrid capita l to EUR 300m

� non-dilutive bond with perpetual maturity, callable at par by Eurofins in Jan 2020

� interest: fixed coupon of 7.00% until first call, Euribor 3m + 818 bp thereafter if not called

Hybrid

OBSAAR

� EUR 176m issued June 2010

� maturity: 1/3 across June 2015, 2016, 2017

Solid Balance Sheet

3.5 x� Net Debt/ Adjusted EBITDA

Dec’13Dec’14

1.90 x

Maximum

� Net Debt (EUR m) 386.8

40

Net Debt calculation

Short-term borrowings

+ Long-term borrowings

- Cash & cash equivalents

= NET DEBT

� Total Equity (EUR m)

� EUR 170m issued in July 2011

� 5-7 year maturity; mid-swap or Euribor 6m + spread of 180-220 bp respectively

Schuldschein

1.76 x

493.6

664.2

� Cash + cash equivalents (EUR m)

297.3216.6

394.7

� EUR 300m Eurobond issued in Nov 2013, 5-yr maturity (2018) at an annual interest of 3.125%

� EUR 500m Eurobond issued in Jan 2015, 7-yr maturity (2022) at an annual interest of 2.25%

Eurobond

1.68 x 1.70 x1.76 x

1.90 x

0.00 x

0.50 x

1.00 x

1.50 x

2.00 x

2.50 x

3.00 x

3.50 x

2011 2012 2013 2014

41

High Degree of Financial Flexibility

41

Net Debt/ Adjusted EBITDA: max 3.5x � Debt ratios remain well below covenant limits despi te EUR 453m* cash invested in the business in 2014 (EUR 215m cash in 2013)

� Largely capex and acquisitions which did not fullycontribute yet in 2014

� Large financial flexibility with fairly long debt maturi ty

�OBSAAR issued in 2010; avg. maturity 2016�Schuldschein issued in 2011; avg. maturity 2017�Hybrid capital of EUR 300m; perpetual, callable 2020�EUR 300m Eurobond issued in 2013; maturing 2018�EUR 500m Eurobond issued in 2015; maturing 2022**

�Revolving Credit Facilities

� Continued profitability improvement means that key debt ratios have slowly increased despite an increa se in absolute amount in Net Debt to EUR 494m from EUR 387m in December 2013

Substantial headroom in the balance sheet

41

* EUR 453m cash investments = EUR 131m capital expen ditures + EUR 292m in acquisitions + EUR 30m one-off restructurin g costs and temporary losses

** Issued in January 2015

42

�Food safety & contamination issues

�New regulations (e.g. FSMA, REACH)

�Outsourcing trend

�Risks due to globalisation of trade

�Vulnerability of global brands

�Scientific developments (e.g. GMOs, Biologics…. ) + new testing methods

Outlook: becoming the world leader in the bioanalyt ical testing market

�Unique technological portfolio of over 130,000 methods

�Volume scale advantage & Competence Centres

�Focus on running labs

�Global network of standardised labs

�Experience in integrating value adding acquisitions

�Recurring revenues with high switching costs and high barriers to entry

+ Key Success FactorsSustainable Market Growth Drivers

Eurofins’ unique position in a young, fast growing and fragmented market should lead to long term, sustainable profitability

= Solid Outlook

43

� EUR 709m of gross senior debt as of 31 December 201 4 (net debt of EUR 493.6m)

� >95% of senior debt in Eurofins Scientific SE (holdi ng level)

� Main facilities in Eurofins Scientific SE:� OBSAAR bonds : EUR 176m� Schuldschein : EUR 170m� Bilateral RCF (undrawn): ca. EUR 300m � Eurobond EUR 300m

� ca. EUR 20m of bank borrowings are secured over bui ldings and assets (in subsidiaries)

� EUR 500m 7-Yr Eurobond issued in January 2015 at a fixed interest rate of 2.25%

� In addition, EUR 300m Hybrid bond (considered equit y under IFRS), non-dilutive bond with perpetual maturity, callable at par by Eu rofins in Jan 2020

Financing facility overview as of 31 December 2014

44

Maturity profile of senior debt at Holding level as of 31 Jan 2015

For private use only – Strictly confidential

Senior debt in Eurofins Scientific SE (EURm)

€ 58.7m

€ 211.7m

€ 58.7m

€ 362m

€ 500m

45

Eurofins dividend payment history

For private use only – Strictly confidential

Eurofins Dividend Payments

46

� Introduction

� Market & Strategic Positioning

� Finance & Outlook

�Transaction Overview

� Summary

� Appendix

Contents

47

Potential transaction rationale

� Eurofins is committed to maintaining a very strong balance sheet with significant headroom to be able to respond swiftly to compelling opportunities, in view of its objective to reach EU R 2bn in revenues by 2017 through a combination of organic growth and ac quisitions

� Use of proceeds would be for organic and external g rowth, as well as general corporate purposes

� The hybrid security would allow Eurofins to strengt hen its balance sheet structure under IFRS

� The instrument would have a good fit with Eurofins’ current financial resources

� The issue would also improve Eurofins’ liquidity po sition by lengthening its debt maturity profile

� Further benefits of this transaction would be favor able interest rate environment and investor diversification

48

Terms & Conditions (1/2)

� Issuer: Eurofins Scientific S.E., acting through its Frenc h Branch

� Offering: Undated [7/8]-Year Non-Call Deeply Subordinate d Fixed to Floating Rate Bonds (the"Bonds")

� Issue rating: Not rated

� Issue size: EUR [ ]m

� Denomination / Listing: EUR 100k + 1k / Luxembourg Stock Ex change (regulated market)

� Ranking: Deeply subordinated; senior to ordinary and prefe rence shares

� Tenor: Perpetual

� Optional call dates: [ ] [2022/2023] and on any floating ra te interest payment date thereafter

� Coupon: [ ]% annual until [ ] [2022/2023], payable annually. Thereafter, if not called, 3-monthEuribor + the initial credit spread + a step-up of [250]bp

� Optional coupon deferral: Optional cumulative and compo unding coupon deferral, subject to dividend pusher

� Dividend pusher: The issuer may not elect to defer in case of , during the 12-month period prior to suchinterest payment date:(i) a distribution, redemption or repurchase in res pect of Share Capital Securities (other than a redemption or repurchase in connectio n with employee benefit or share option plans, or with the exercise of certain warra nts, provided it does not exceed 10% of the principal of the Bonds in a 12-month per iod);(ii) a distribution, redemption or repurchase in re spect of any Accounting Equity Securities of the Issuer; and(iii) a redemption or repurchase in respect of any Parity Securities,provided that such distribution, redemption, or rep urchase is at Issuer’s discretion

49

Terms & Conditions (2/2)

� Settlement of Outstanding Amounts:

Optional settlement at any time; must be settled upon intere st payment on theBonds, a pusher event, redemption of the Bonds, liquidation of the Issuer

� Interest on interest: Outstanding Amounts bear interes t at the rate of interest then applicable to theBonds. No interest on deferred coupons applies for the first 12 months followingthe initial date of coupon deferral

� Change of Control Event: If a change of control has occurr ed and the Issuer has not obtained an investmentgrade credit rating, the coupon steps up by 250bps if Bonds no t called

� Early redemption options: Withholding Tax Event, Chang e of Control Event, Substantial Repurchase Event(<75% outstanding) (each at par);Tax Deductibility Event, Accounting Event (each at 101% unt il the first call date, atpar thereafter)

� Restrictions on Shareholder Indebtedness:

In the event that there are Outstanding Amounts, the Issuer u ndertakes that it willnot (i) accept a loan, credit or other facility from any Signi ficant Shareholder orRelated Party ranking senior to the Notes, (ii) pay interest on any loan, credit orother facility to a Significant Shareholder or Related Part y and (iii) give a loan, creditor other facility to any Significant Shareholder or Related Party“Significant Shareholder” means any person or persons in con cert who at any timehold directly or indirectly more than 10% of the shares or the voting rights

� Claim in liquidation: Notional plus any accrued and unpa id interest plus Outstanding Amounts andinterest accrued thereon

� Governing law: Luxembourg law

Dividend Pusher MechanismConventional structure with investor friendly enhancements

Interest Deferral Date

12m 12m 12m

Interest accrues on outstanding principal amount

only (“interest on interest” does not apply)

Interest accrues on principal and Outstanding Amounts(“interest on interest” applies)

Interest on Interest

Issuer may choose to defer interest at its

discretion

Current interest mustbe paid by the Issuer

Current interest and any Outstanding

Amounts must be paid by the issuer

Issuer may choose to defer interest at its

discretion

“Dividend Pusher” Triggered?

“Dividend Pusher” Triggered?

“Dividend Pusher” Triggered?

YES YES

NO NO

YES

“Dividend Pusher”:• Obligation to pay accrued interest and Outstanding Amounts in cash on an interest payment date in case of distribution, redemption or

repurchase in respect of Share Capital Securities o r Accounting Equity Securities, and redemption or r epurchase of Parity Securities, during the preceding 12 months

• Customary exemptions apply to share repurchases or redemptions (in connection with stock option plans and existing warrants) for volumes of up to 10% of the aggregate principal amount of t he Bonds

Current interest and any Outstanding

Amounts must be paid by the issuer

NO

In case of deferral: the issuer undertakes that it will not (i) accept a loan, credit or other facility from any Significant Shareholder ranking senior to the Bonds, (ii) give a loan, credit or other

facility to any Significant Shareholder and (iii) pay interest on any loan, credit or other facility to a Significant Shareholder, in each case to the extent such loan, credit or other facility is material

Shareholder Indebtedness

RestrictionNo restriction

Issuer may choose to defer interest at its

discretion

Not applicable

51

� Introduction

� Market & Strategic Positioning

� Finance & Outlook

�Transaction Overview

� Summary

� Appendix

Contents

52

High-growth, non-cyclical markets driven by secular

mega-trends

Advancing globalisation but with very few global

testing suppliers

Fragmented competition & opportunities for

consolidation

Very recurring business; 6% - 12% historic organic

growth

High barriers to entry

Best in class technology and quality give best brand

protection

No. 1 or 2 worldwide in most business lines

Strong international presence in 36 countries

State-of-the-art laboratory infrastructure

High switching costs for clients

Good cash flow visibility

Experienced multi-national leadership

Conclusion: our sustainable competitive advantage

� Track record of profitable growth – Strong ROCE and cash flow generation potential

� ROCE* of 14.7% and ROE** of 20.0% in 2014 despite significant future-orientated investments and one-off restructuring

costs

� 5-year CAGR: Revenues 17.1%, Operating Cash Flow 27.0%

� Large potential to roll out business model in fast growing economies

� Following the last intense investment cycle (2006-2010), Eurofins is well-positioned to double in size and reach EUR

2bn in revenues by 2017 whilst maintaining leadership in multiple markets and improving profitability

*ROCE = EBITAS/Average Capital Employed over previous 4 quarters **ROE = Net Profit/Equity at the beginning of the year

53

Appendix / Back up slides

54

Consolidated Income Statement

2014 2013

EUR Thousands Adjusted results

Separately disclosed

items

Reported results

Adjusted results

Separately disclosed

items

Reported results

Revenues 1,410,227 - 1,410,227 1,225,572 - 1,225,572 Operating costs, net -1,149,797 -30,420 -1,180,217 -1,006,291 -30,191 -1,036,482 EBITDA 260,430 -30,420 230,010 219,281 -30,191 189,090 Depreciation and amortisation -70,546 -10,737 -81,283 -57,380 -9,500 -66,880 EBITAS 189,884 -41,157 148,727 161,901 -39,691 122,210 Non-cash stock option charge and acquisition-related expenses, net - -16,889 -16,889 - -9,977 -9,977

EBIT 189,884 -58,046 131,838 161,901 -49,668 112,233 Finance income 2,232 - 2,232 1,112 - 1,112 Finance costs -32,980 - -32,980 -24,570 - -24,570 Share of (loss)/ profit of associates 243 - 243 288 - 288 Profit before income tax 159,378 -58,046 101,332 138,731 -49,668 89,063 Income tax expense -31,131 8,930 -22,201 -22,049 4,879 -17,170 Net profit and loss for the period 128,247 -49,116 79,131 116,682 -44,789 71,893 Net profit and loss attributable to:

� Equity holders of the Company 128,195 -49,091 79,104 116,759 -44,579 72,180 � Non-controlling interests 52 -25 27 -77 -210 -287

Adjusted – reflects the ongoing performance of the mature and recurring activities excluding “separately disclosed items”.Separately disclosed items – includes one-off costs from integration, reorganisation, discontinued operations and other non-recurring income and costs, temporary losses and other costs related to network expansion, start-ups and new acquisitions undergoing significant restructuring, non-cash accounting charges for stock options, impairment of goodwill, amortisation of acquired intangible assets, negative goodwill and transaction costs related to acquisitions as well as income from reversal of such costs and from unused amounts due for business acquisitions and the related tax effects.

55

Consolidated Balance Sheet

EUR Thousands 2014 2013 Property, plant and equipment 323,747 251,113 Goodwill 679,030 456,388 Other intangible assets 193,534 86,382 Investments in associates 2,887 4,594 Financial assets and other receivables 23,264 16,805 Deferred tax assets 26,333 32,757 Total non-current assets 1,248,795 848,039 Inventories 24,623 20,141 Trade accounts receivable 321,476 272,650 Prepaid expenses and other current assets 43,625 34,353 Current income tax assets 14,728 20,141 Cash and cash equivalents 216,620 297,257 Total current assets 621,072 644,542

Assets classified as held for sale 3,323 4,435 Total assets 1,873,190 1,497,016 Share capital 1,520 1,507 Hybrid capital 300,000 150,000 Other reserves 105,510 98,699 Retained earnings 220,986 154,235 Currency translation differences 28,467 -16,755 Total attributable to equity holders of the Company 656,483 387,686 Non-controlling interests 7,758 7,054 Total shareholders' equity 664,241 394,740

Borrowings 638,054 666,875 Derivative financial instruments 12,362 15,119 Deferred tax liabilities 42,274 28,965 Amounts due for business acquisitions 25,235 16,928 Retirement benefit obligations 34,616 30,691 Provisions for other liabilities and charges 4,903 4,985 Total non-current liabilities 757,444 763,563 Borrowings 72,178 17,228 Interest and earnings due on hybrid capital 23,832 14,123 Trade accounts payable 127,141 100,951 Advance payments received 18,621 14,369 Deferred revenues 18,804 16,764 Current income tax liabilities 11,476 20,934 Amounts due for business acquisitions 19,073 9,892 Provisions for other liabilities and charges 8,279 10,881 Other current liabilities 152,101 133,571 Total current liabilities 451,505 338,713

Total liabilities and shareholders' equity 1,873,190 1,497,016

56

Consolidated Cashflow Statement

EUR Thousands 2014 2013 Cash flows from operating activities Result before income taxes 101,332 89,063 Adjustments for: Depreciation and amortisation 81,283 66,880 Non-cash stock option charge and acquisition-related expenses, net 16,889 9,977 Other non-cash effects 3,285 862 Financial income and expense, net 30,701 22,302 Share of profit from associates -243 -288 Transactions costs and income related to acquisitions -1,605 -2,233 Increase (decrease) in provisions, retirement benefit obligations -4,276 -531 Change in net working capital 17,077 13,773 Cash generated from operations 244,443 199,805 Income taxes paid -32,270 -30,466 Net cash provided by operating activities 212,173 169,338 Cash flows from investing activities Acquisitions of subsidiaries, net of cash acquired -291,798 -87,437 Purchase of property, plant and equipment -105,506 -79,229 Purchase, capitalisation of intangible assets -29,018 -20,327 Proceeds from sale of property, plant and equipment 3,334 832 Change in investments and financial assets, net -1,631 -3,987 Interest received 2,233 1,130 Net cash used in investing activities -422,386 -189,018 Cash flows from financing activities Proceeds from issuance of share capital 6,898 7,992 Proceeds from borrowings 41,277 325,261 Repayments of borrowings -27,220 -83,651 Change in hybrid capital 163,316 -9,114 Dividends paid to shareholders and non-controlling interests -18,314 -15,485 Earnings paid to hybrid capital investors -5,667 -9,666 Interest paid -30,476 -21,370 Net cash provided by financing activities 129,814 193,967 Net effect of currency translation on cash and cash equivalents and bank overdrafts 2,221 -3,236

Net increase (decrease) in cash and cash equivalent s and bank overdrafts -78,178 171,051 Cash and cash equivalents and bank overdrafts at beginning of period 293,268 122,217 Cash and cash equivalents and bank overdrafts at en d of period 215,090 293,268

Eurofins has vastly outperformed the market since its IPO and each of its 3 equity offerings (based on share price of EUR 212.05 as of 31 December 2014)

1997 € 5m

1998rights issue€ 6m

SPO 1

1999rights issue€ 7m

SPO 2

2000 SPO

€ 38.5m

SPO 3

Eurofins: +11,484% (32% CAGR)CAC 40: +54% (3% CAGR)SBF 120: +78% (3% CAGR)

S&P 500: +135% (5% CAGR)

Eurofins: +2,593% (23% CAGR)CAC 40: +20% (1% CAGR)SBF 120: +39% (2% CAGR)S&P 500: +93% (4% CAGR)

Eurofins: +2,670% (25% CAGR)CAC 40: -9% (-1% CAGR)SBF 120: 5% (0% CAGR)

S&P 500: +59% (3% CAGR)

Eurofins: +393% (12% CAGR)CAC 40: -32% (-3% CAGR)SBF 120: -20% (-2% CAGR)S&P 500: +49% (3% CAGR)

Eurofins: +1166% (29% CAGR)CAC 40: +12% (1% CAGR)SBF 120: +24% (2% CAGR)S&P 500: +70% (5% CAGR)

10 years

Since SPO 2

Since SPO 1

Since IPO

Since SPO 3

2 years

Eurofins: +73% (32% CAGR)CAC 40: 17% (8% CAGR)

SBF 120: 20% (10% CAGR)S&P 500: +44% (20% CAGR)

5 yearsEurofins: +455% (41% CAGR)

CAC 40: 9% (2% CAGR)SBF 120: 18% (3% CAGR)

S&P 500: +85% (13% CAGR)

Total equity raised in 4 offerings: only EUR 56m

57

IPO

58

Post acquisition and integration into Eurofins, bot h sales and profits increase significantly

Illustration

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004

Annual Sales / million

Acquired by

Eurofins

CAGR19%

EBITA margin in % of sales

<8% >20%

Growth drivers post acquisition:

1) Sales increase through cross selling of Eurofins lab specialities internationally

2) Cost reduction – focus on most frequently performed tests

Frequency(e.g. no. of

tests per day)

No. of tests offered

100

Prior to acquisition

50% 50%% of employees performing tests

Can be subcontracted to specialised Eurofins laboratories after acquisition

400

Focus and scale drive profitability

Actual example of an acquired lab:

100

50

500

Company A